Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARTER: Chidamide with ART for HIV Latent Reservoir Eradication
NCT02513901Phase 2Completed
- Sponsor
- Tangdu Hospital
- Start
- Aug 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Change in plasma HIV-1 RNA at Day 56. Started Aug 2015; status: completed.
02
Drugs
tucidinostat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02513901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513901.